Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)

Pier Luigi Zinzani, MD, Vincent Delwail, Shankara Paneesha, MD, Simon Rule, MD PhD, Alejandro Martin Garcia-Sancho, MD PhD, Ana Marin-Niebla, MD PhD, Gilles Salles, MD PhD, Juan-Manuel Sancho, MD PhD, Vibeke Vergote, MD, Vittorio Ruggero Zilioli, MD, Fred Zheng, MD, Douglas J DeMarini, PhD, Wei Jiang, PhD, Amitkumar Mehta, MD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-134609

Published: 2020

Journal Articles

Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy

Gloria Iacoboni, MD, Marc Simo, MD, Guillermo Villacampa, Eva Catala, Cecilia Carpio, MD, Candido Diaz-Lagares, MD, Angela Vidal-Jordana, MD, Sabela Bobillo, MD, Ana Marin-Niebla, MD PhD, Ana Perez, MD, Moraima Jiménez, Pau Abrisqueta, MD PhD, David Valcárcel, MD PhD, Francesc Bosch, MD PhD, Pere Barba, MD PhD

Blood (2020) 136 (Supplement 1): 27–29.

https://doi.org/10.1182/blood-2020-141777

Published: 2020

Journal Articles

Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL)

Ana Marin-Niebla, MD, Monica Else, MA, MSc, Fatima De la Cruz, MD, Paul Batty, MD, Eduardo Rios-Herranz, MD, Claire E. Dearden, Ildefonso Espigado, MD, PhD, Jose Antonio Pérez Simón, MD, PhD, Daniel Catovsky, MD, Estella Matutes

Blood (2011) 118 (21): 4986.

https://doi.org/10.1182/blood.V118.21.4986.4986

Published: 2011

Journal Articles

Low-Intensity Fludarabine, Cyclophosphamyde, Rituximab (FCR) as Front-Line Treatment for Follicular Lymphoma. Efficacy and Toxicity Profile of the Oral Versus Intravenous Administration.

Ana Marin-Niebla, MD, Eduardo Rios-Herranz, MD, Fáatima de la Cruz Vicente, Jr., MD, Paula Cerezuela, MD, Jose Francisco Falantes, MD, Mariluz Martino, MD, Ildefonso Espigado, Alvaro Urbano Ispizua, MD, PhD

Blood (2009) 114 (22): 2690.

https://doi.org/10.1182/blood.V114.22.2690.2690

Published: 2009

Journal Articles

Incidence of Neutropenia and Hypogammaglobulinemia and Correlation with the Infections Rate in Indolent Non-Hodgkin Lymphoma (NHL) Receiving Rituximab Maintenance.

Ana Marin-Niebla, MD, Eduardo Rios-Herranz, MD, Jose F. Falantes, MD, Mariluz Martino, MD, Ildefonso Espigado, MD PhD, Alvaro Urbano-Ispizua, MD PhD

Blood (2007) 110 (11): 4495.

https://doi.org/10.1182/blood.V110.11.4495.4495

Published: 2007

Journal Articles

Efficacy and Safety of Fludarabine/Cyclophosphamide (FC) as Front-Line Treatment of CLL. Final Results of a Phase II Clinical Trial in a Single Center.

Ana Marin-Niebla, MD, Eduardo Rios-Herranz, MD, Juan M. Rodriguez, PhD, Ramiro Nunez, MD, Ascension Herrera, MD, Ricardo Parody, MD, Ildefonso Espigado, PhD.

Blood (2004) 104 (11): 4826.

https://doi.org/10.1182/blood.V104.11.4826.4826

Published: 2004

NARROW

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)

Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy

Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL)

Low-Intensity Fludarabine, Cyclophosphamyde, Rituximab (FCR) as Front-Line Treatment for Follicular Lymphoma. Efficacy and Toxicity Profile of the Oral Versus Intravenous Administration.

Incidence of Neutropenia and Hypogammaglobulinemia and Correlation with the Infections Rate in Indolent Non-Hodgkin Lymphoma (NHL) Receiving Rituximab Maintenance.

Efficacy and Safety of Fludarabine/Cyclophosphamide (FC) as Front-Line Treatment of CLL. Final Results of a Phase II Clinical Trial in a Single Center.

Email alerts

ASH Publications

American Society of Hematology

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)

Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy

Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL)

Low-Intensity Fludarabine, Cyclophosphamyde, Rituximab (FCR) as Front-Line Treatment for Follicular Lymphoma. Efficacy and Toxicity Profile of the Oral Versus Intravenous Administration.

Incidence of Neutropenia and Hypogammaglobulinemia and Correlation with the Infections Rate in Indolent Non-Hodgkin Lymphoma (NHL) Receiving Rituximab Maintenance.

Efficacy and Safety of Fludarabine/Cyclophosphamide (FC) as Front-Line Treatment of CLL. Final Results of a Phase II Clinical Trial in a Single Center.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only